OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS ® powered with SOPHiA DDMTM BOSTON and ROLLE, Switzerland , July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH ), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that OncoHelix, an internationally recognized research and diagnostics laboratory for precision diagnostics, will implement MSK-ACCESS ® powered with SOPHiA DDMTM . The organization, which currently uses the SOPHiA DDMTM Platform for myeloid testing, will use the new liquid biopsy solution to advance its oncology testing capabilities. OncoHelix will be live on MSK-ACCESS ® powered with SOPHiA DDMTM later this summer.
OncoHelix is based in Calgary, Canada , and offers specialized genomic and molecular testing services globally. OncoHelix works in partnership with the Hematology Translational Lab (HTL) at the University of Calgary and has helped significantly advance the University's precision oncology and immunology research pipelines. "Our mission at OncoHelix is to offer exceptional clinical-grade molecular and immune profile testing.
That mission is predicated on using the most cutting-edge technology to allow for the rapid validation of genomic panels, sequencing, and analysis," said Dr. Pinaki Bose , Co-founder and Executive Vice President, OncoHelix. "The SOPHiA DDMTM Platform has supported our mission over the last year, and we look forward to implementing MSK-ACCESS ® powered with SOP.